Log in
Enquire now
SalioGen Therapeutics

SalioGen Therapeutics

SalioGen Therapeutics is a gene Therapy Platform Technology.

OverviewStructured DataIssuesContributors

Contents

saliogen.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Biomedical engineering
Biomedical engineering
Engineering
Engineering
Biotechnology
Biotechnology
Location
Burlington, Massachusetts
Burlington, Massachusetts
Cambridge, Massachusetts
Cambridge, Massachusetts
United States
United States
Pitchbook URL
pitchbook.com/profiles...460323-10
Email Address
investors@saliogen.com0
info@saliogen.com0
media@saliogen.com0
jobs@saliogen.com0
Phone Number
+185799022000
Full Address
245 First Street, 18th Floor, Cambridge, MA 02142, USA0
Investors
Fidelity Investments
Fidelity Investments
Cystic Fibrosis Foundation
Cystic Fibrosis Foundation
D1 Capital Partners
D1 Capital Partners
PBM Capital
PBM Capital
EPIQ Capital Group
EPIQ Capital Group
Total Funding Amount (USD)
115,000,000
Latest Funding Round Date
January 5, 2022
Latest Funding Type
Series B
Series B
Country
United States
United States

Other attributes

Company Operating Status
Active
Latest Funding Round Amount (USD)
115,000,000
No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like SalioGen Therapeutics

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.